
|Articles|March 1, 2003
How to use intravesical chemo post-TUR to treat TCC
The predictable recurrence of superficial transitional cell carcinoma of the urinary bladder is responsible for the frequent utilization of intravesical therapy. In the past 2 years, we have changed our intravesical treatment strategy at Ohio State University in an effort to enhance efficacy and reduce patient inconvenience.
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Mohit Khera, MD, recaps key takeaways from FDA panel on TRT for men
2
FDA approves first-line Zenflow system for the treatment of BPH
3
FDA approves niraparib plus abiraterone acetate with prednisone for BRCA2+ mCSPC
4
FDA approves zoliflodacin for uncomplicated urogenital gonorrhea
5















